Subscribe To

Price Alert Latest News Economic Calendar News

ISEE / IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2022 Results - Earnings Call Transcript

IVERIC bio, Inc. (NASDAQ:ISEE ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Kathy Galante - SVP of IR Glenn Sblendorio - CEO Pravin Dugel - President Keith Westby - COO David Carroll - CFO Dhaval Desai - Chief Development Officer Chris Simms - Chief Commercial Officer Tony Gibney - Chief Business and Strategy Officer Conference Call Participants Georgi Yordanov - Cowen & Company Annabel Samimy - Stifel Tiago Fauth - Credit Suisse Chris Howerton - Jefferies Colleen Kusy - Baird Operator Hello, and welcome to the IVERIC bio, Inc. First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded. Read More

Demo Live Account See Partner Details

Content Topics

Iveric

Bio

Inc

ISEE

Glenn

Sblendorio

2022

Results

isee

Earnings

Transcript

Stock

Posted: May 4 2022, 14:04

Author Name: Seeking Alpha

ISEE News

By Bloomberg Markets and Finance
May 1, 2023

Astellas Pharma CEO Says Confident of Iveric Bio Drug Approval

Naoki Okamura, chief executive officer of Japanese drugmaker Astellas Pharma Inc., discusses his company's decision to acquire Iveric Bio Inc., a de

By Barrons
May 1, 2023

Iveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.

Japan's Astellas agrees to pay $40 a share for Iveric, citing the potential of the biopharmaceutical company's ophthalmology programs.

By Market Watch
May 1, 2023

Japan's Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion

Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology

By InvestorPlace
November 18, 2022

Why Is Iveric Bio (ISEE) Stock Up 25% Today?

Against a relatively flat backdrop for the major equity indices, biotechnology firm Iveric Bio (NASDAQ: ISEE ) provided a decisively positive framewor

By Seeking Alpha
November 5, 2022

IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript

IVERIC bio, Inc. (NASDAQ:ISEE ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Kathy Galante - SVP, IR & Corporate

By Zacks Investment Research
September 7, 2022

IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study

IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment

By Seeking Alpha
September 7, 2022

Iveric bio: Further Upside Possible Based On Expanded Opportunities With Zimura

Positive results achieved in both GATHER1 and GATHER2 studies, whereby Zimura met prespecified primary endpoints of Mean rate of GA growth compared to

By InvestorPlace
September 6, 2022

Why Is Iveric Bio (ISEE) Stock Up 56% Today?

Source: Shutterstock / PopTika Iveric Bio (NASDAQ: ISEE ) stock is rising higher on Tuesday after the biopharmaceutical company revealed positive resu

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.